Literature DB >> 11854220

Pulmonary inflammation induced by Pseudomonas aeruginosa lipopolysaccharide, phospholipase C, and exotoxin A: role of interferon regulatory factor 1.

Catharina W Wieland1, Britta Siegmund, Giorgio Senaldi, Michael L Vasil, Charles A Dinarello, Giamila Fantuzzi.   

Abstract

Chronic pulmonary infection with Pseudomonas aeruginosa is common in cystic fibrosis (CF) patients. P. aeruginosa lipopolysaccharide (LPS), phosholipase C (PLC), and exotoxin A (ETA) were evaluated for their ability to induce pulmonary inflammation in mice following intranasal inoculation. Both LPS and PLC induced high levels of tumor necrosis factor alpha (TNF-alpha), interleukin 1 beta (IL-1 beta-6, gamma interferon (IFN-gamma), MIP-1 alpha MIP-2 in the lungs but did not affect IL-18 levels. ETA did not induce TNF-alpha and was a weak inducer of IL-1 beta, IL-6, macrophage inflammatory protein 1 alpha (MIP-1 alpha), and MIP-2. Remarkably, ETA reduced constitutive lung IL-18 levels. LPS was the only factor inducing IFN-gamma. LPS, PLC, and ETA all induced cell infiltration in the lungs. The role of interferon regulatory factor-1 (IRF-1) in pulmonary inflammation induced by LPS, PLC, and ETA was evaluated. When inoculated with LPS, IRF-1 gene knockout (IRF-1 KO) mice produced lower levels of TNF-alpha, IL-1 beta, and IFN-gamma than did wild-type (WT) mice. Similarly, a milder effect of ETA on IL-1 beta and IL-18 was observed for IRF-1 KO than for WT mice. In contrast, the cytokine response to PLC did not differ between WT and IRF-1 KO mice. Accordingly, LPS and ETA, but not PLC, induced expression of IRF-1 mRNA. IRF-1 deficiency had no effect on MIP-1 alpha and MIP-2 levels and on cell infiltration induced by LPS, PLC, or ETA. Flow cytometric evaluation of lung mononuclear cells revealed strongly reduced percentages of CD8(+) and NK cells in IRF-1 KO mice compared to percentages observed for WT mice. These data indicate that different virulence factors from P. aeruginosa induce pulmonary inflammation in vivo and that IRF-1 is involved in some of the cytokine responses to LPS and ETA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11854220      PMCID: PMC127789          DOI: 10.1128/IAI.70.3.1352-1358.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.609


  39 in total

1.  In vivo alterations of IFN regulatory factor-1 and PIAS1 protein levels in cystic fibrosis epithelium.

Authors:  T J Kelley; H L Elmer
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

2.  The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type.

Authors:  C Moser; S Kjaergaard; T Pressler; A Kharazmi; C Koch; N Høiby
Journal:  APMIS       Date:  2000-05       Impact factor: 3.205

Review 3.  Extracellular toxins of Pseudomonas aeruginosa.

Authors:  P V Liu
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

4.  Protection against the mortality associated with disease models mediated by TNF and IFN-gamma in mice lacking IFN regulatory factor-1.

Authors:  G Senaldi; C L Shaklee; J Guo; L Martin; T Boone; T W Mak; T R Ulich
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

5.  In vivo studies with two phospholipase C fractions from Pseudomonas aeruginosa.

Authors:  R S Berk; D Brown; I Coutinho; D Meyers
Journal:  Infect Immun       Date:  1987-07       Impact factor: 3.441

6.  Tumour necrosis factor-alpha and interferon-gamma synergistically activate the RANTES promoter through nuclear factor kappaB and interferon regulatory factor 1 (IRF-1) transcription factors.

Authors:  A H Lee; J H Hong; Y S Seo
Journal:  Biochem J       Date:  2000-08-15       Impact factor: 3.857

7.  Role of interferon regulatory factor-1 in the regulation of IL-18 production and activity.

Authors:  G Fantuzzi; D Reed; M Qi; S Scully; C A Dinarello; G Senaldi
Journal:  Eur J Immunol       Date:  2001-02       Impact factor: 5.532

8.  Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure.

Authors:  V Y Melnikov; T Ecder; G Fantuzzi; B Siegmund; M S Lucia; C A Dinarello; R W Schrier; C L Edelstein
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

9.  Mechanism of action of Pseudomonas aeruginosa exotoxin A in experimental mouse infections: adenosine diphosphate ribosylation of elongation factor 2.

Authors:  O R Pavlovskis; B H Iglewski; M Pollack
Journal:  Infect Immun       Date:  1978-01       Impact factor: 3.441

10.  An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes.

Authors:  T Tamura; M Ishihara; M S Lamphier; N Tanaka; I Oishi; S Aizawa; T Matsuyama; T W Mak; S Taki; T Taniguchi
Journal:  Nature       Date:  1995-08-17       Impact factor: 49.962

View more
  28 in total

1.  Rhesus θ-Defensin-1 Attenuates Endotoxin-induced Acute Lung Injury by Inhibiting Proinflammatory Cytokines and Neutrophil Recruitment.

Authors:  Jordanna G Jayne; Timothy J Bensman; Justin B Schaal; A Young J Park; Elza Kimura; Dat Tran; Michael E Selsted; Paul M Beringer
Journal:  Am J Respir Cell Mol Biol       Date:  2018-03       Impact factor: 6.914

2.  Hemolytic phospholipase C inhibition protects lung function during Pseudomonas aeruginosa infection.

Authors:  Matthew J Wargo; Maegan J Gross; Sathish Rajamani; Jenna L Allard; Lennart K A Lundblad; Gilman B Allen; Michael L Vasil; Laurie W Leclair; Deborah A Hogan
Journal:  Am J Respir Crit Care Med       Date:  2011-05-11       Impact factor: 21.405

3.  Microevolution of cytochrome bd oxidase in Staphylococci and its implication in resistance to respiratory toxins released by Pseudomonas.

Authors:  Lalitha Voggu; Steffen Schlag; Raja Biswas; Ralf Rosenstein; Christian Rausch; Friedrich Götz
Journal:  J Bacteriol       Date:  2006-12       Impact factor: 3.490

4.  Type II secretion system of Pseudomonas aeruginosa: in vivo evidence of a significant role in death due to lung infection.

Authors:  Jeevan Jyot; Viviane Balloy; Gregory Jouvion; Amrisha Verma; Lhousseine Touqui; Michel Huerre; Michel Chignard; Reuben Ramphal
Journal:  J Infect Dis       Date:  2011-05-15       Impact factor: 5.226

5.  Role of Toll interleukin-1 receptor (IL-1R) 8, a negative regulator of IL-1R/Toll-like receptor signaling, in resistance to acute Pseudomonas aeruginosa lung infection.

Authors:  Tania Véliz Rodriguez; Federica Moalli; Nadia Polentarutti; Moira Paroni; Eduardo Bonavita; Achille Anselmo; Manuela Nebuloni; Stefano Mantero; Sébastien Jaillon; Alessandra Bragonzi; Alberto Mantovani; Federica Riva; Cecilia Garlanda
Journal:  Infect Immun       Date:  2011-10-24       Impact factor: 3.441

6.  Cellular choline and glycine betaine pools impact osmoprotection and phospholipase C production in Pseudomonas aeruginosa.

Authors:  Liam F Fitzsimmons; Ken J Hampel; Matthew J Wargo
Journal:  J Bacteriol       Date:  2012-06-29       Impact factor: 3.490

7.  Pseudomonas aeruginosa induces localized immunosuppression during pneumonia.

Authors:  Maureen H Diaz; Ciara M Shaver; John D King; Srinidhi Musunuri; Jeffrey A Kazzaz; Alan R Hauser
Journal:  Infect Immun       Date:  2008-07-28       Impact factor: 3.441

8.  Proteolytic cleavage of a C-terminal prosequence, leading to autoprocessing at the N Terminus, activates leucine aminopeptidase from Pseudomonas aeruginosa.

Authors:  Robert Sarnovsky; Jennifer Rea; Matt Makowski; Ralf Hertle; Colleen Kelly; Antonella Antignani; Diana V Pastrana; David J Fitzgerald
Journal:  J Biol Chem       Date:  2009-02-11       Impact factor: 5.157

Review 9.  Homeostasis and catabolism of choline and glycine betaine: lessons from Pseudomonas aeruginosa.

Authors:  Matthew J Wargo
Journal:  Appl Environ Microbiol       Date:  2013-01-25       Impact factor: 4.792

10.  GbdR regulates Pseudomonas aeruginosa plcH and pchP transcription in response to choline catabolites.

Authors:  Matthew J Wargo; Tiffany C Ho; Maegan J Gross; Laurie A Whittaker; Deborah A Hogan
Journal:  Infect Immun       Date:  2008-12-22       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.